Plaintiffs product liability lawsuits against the manufacturers of Xarelto are encouraged by actions taken with another new-generation blood thinner called Pradaxa that shares many similarities with the drug Xarelto.
Pradaxa was released on the market for use by consumers in 2010 by Boehringer Ingelheim.
Pradaxa became the focus of public attention, as it was the subject of more than 3,500 adverse event reports with fatalities in over 750 of them. It subsequently became the focus of over 4,000 lawsuits.
$650 million settlement
Rather than go to trial, Pradaxa’s maker opted to settle all the lawsuits with a $650 million settlement. It is the hope of many of the plaintiffs in the Xarelto cases that they will also be the beneficiaries of a settlement by the makers of Xarelto.
Xarelto defendants include Janssen Pharmaceuticals and Bayer AG, the former of which is a subsidiary of the Johnson and Johnson Corporation. The U.S. Judicial Panel on Multidistrict Litigation (JPML) decreed that because the cases filed were strikingly similar in the allegations of uncontrollable bleeding being leveled at the manufacturers, it consolidated the cases together, which now contains over 2,800 complaints. In the month of August 2015 alone, the cases included in the multidistrict litigation (MDL 2592 in Louisiana) have grown by 400 cases, and the MDL is expected to increase further.
The court in Xarelto MDL 2592 Federal Litigation has set four cases for trial in the spring of 2017 in the Eastern District of Louisiana.
- February 6
- March 13
- April 24
- May 30
Judge Eldon E. Fallon selected these bellwether cases from an initial pool of 40 lawsuits.
In addition to the cases in the MDL, there is an additional group of lawsuits in excess of 550 that were consolidated into a mass tort group by the Court of Common Pleas in Philadelphia, PA. All plaintiffs in these cases have named Janssen and Bayer AG as defendants as well.